Exhibit 10.1


 


Execution Version 


SUPPORT AGREEMENT 


 


This SUPPORT AGREEMENT
(this “Agreement”), is made as of March 16, 2017, by and between Molecular Templates, Inc. (“Molecular”)
and the Person set forth on Schedule A hereto (the “Stockholder”).


 


WHEREAS, as
of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.001 per share (“Common
Stock”), of Threshold Pharmaceuticals, Inc., a Delaware corporation (“Threshold”), set
forth opposite the Stockholder’s name on Schedule A (all such shares set forth on Schedule A, together with
any shares of Common Stock that are hereafter issued to or otherwise acquired, whether beneficially or of record, or owned by the
Stockholder prior to the termination of this Agreement being referred to herein as the “Subject Shares”);


 


WHEREAS, Molecular,
Trojan Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Threshold (“Merger Sub”)
and Threshold propose to enter into an Agreement and Plan of Merger and Reorganization, dated as of the date hereof (the “Merger
Agreement”), which provides, among other things, for the merger of Merger Sub with and into Molecular, with Molecular
continuing as the surviving corporation (the “Merger”), upon the terms and subject to the conditions
set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed
to such terms in the Merger Agreement); and


 


WHEREAS, as
a condition to its willingness to enter into the Merger Agreement, Molecular has required that the Stockholder, and as an inducement
and in consideration therefor, the Stockholder (in the Stockholder’s capacity as a holder of the Subject Shares) has agreed
to, enter into this Agreement.


 


NOW, THEREFORE,
in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending
to be legally bound, do hereby agree as follows:


 


ARTICLE I 


 


VOTING AGREEMENT; GRANT OF PROXY 


 


The Stockholder hereby covenants and agrees
that:


 


1.1. Voting
of Subject Shares. From and after the date hereof, at every meeting of the holders of Threshold Common Stock (the “Threshold
Stockholders”), however called, and at every adjournment or postponement thereof, the Stockholder shall, or shall
cause the holder of record on any applicable record date to, be present (in person or by proxy) and to vote the Stockholder’s
Subject Shares (a) in favor of (A) the issuance of shares of Threshold Common Stock to the Molecular Stockholders pursuant
to the terms of the Merger Agreement, (B) if requested by Molecular prior to the filing with the SEC of the Proxy Statement / Prospectus
/ Information Statement, the amendment of Threshold’s certificate of incorporation to increase the authorized shares of Threshold
Common Stock, (C) the amendment of Threshold’s Certificate of Incorporation to effect the Reverse Split, (D) the amendment
of Threshold’s certificate of incorporation to effect the name change of Threshold, (E) if requested by Molecular prior to
the filing with the SEC of the Proxy Statement / Prospectus / Information statement, adoption of a new equity incentive plan and/or
an employee stock purchase plan, with share reserve amounts recommended by the Molecular Board of Directors or a committee thereof,
and (F) in accordance with Section 14A of the Exchange Act and the applicable SEC rules issued thereunder, seeking advisory approval
of a proposal to the Threshold


 




    1 


     


    

Stockholders for a non-binding, advisory
vote to approve certain compensation that may become payable to Threshold’s named executed officers in connection with the
completion of the Merger, if applicable; and (b) against any Acquisition Proposal. The Stockholder shall retain at all times
the right to vote the Stockholder’s Subject Shares in Stockholder’s sole discretion and without any other limitation
on those matters other than those set forth in this Section 1.1 that are at any time or from time to time presented for
consideration to the Threshold Stockholders.


 


1.2. No Inconsistent
Arrangements. Except as provided hereunder or under the Merger Agreement, the Stockholder shall not, directly or indirectly,
(a) create any Encumbrance other than restrictions imposed by Legal Requirements or pursuant to this Agreement on any Subject
Shares, (b) transfer, sell, assign, gift or otherwise dispose of (collectively, “Transfer”), or
enter into any contract with respect to any Transfer of the Subject Shares or any interest therein, (c) grant or permit the
grant of any proxy, power of attorney or other authorization in or with respect to the Subject Shares, (d) deposit or permit
the deposit of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject
Shares, or (e) take any action that, to the knowledge of the Stockholder, would make any representation or warranty of the
Stockholder herein untrue or incorrect in any material respect, or have the effect of preventing the Stockholder from performing
the Stockholder’s obligations hereunder. Notwithstanding the foregoing, (i) the Stockholder may (A) make transfers of
the Subject Shares as charitable gifts or donations, (B) make transfers or dispositions of the Subject Shares to any trust for
the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder, (C) make transfers or dispositions
of the Subject Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary
or a member of the immediate family of the Stockholder, (D) make transfers of the Subject Shares to stockholders, direct or indirect
affiliates (within the meaning set forth in Rule 405 under the Securities Act of 1933, as amended), current or former partners
(general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates,
partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that
controls, is controlled by or is under common control with the Stockholder, (E) make transfers that occur by operation of law pursuant
to a qualified domestic order or in connection with a divorce settlement, (F) make transfers or dispositions not involving a change
in beneficial ownership, and (G) if the Stockholder is a trust, make transfers or dispositions to any beneficiary of the Stockholder
or the estate of any such beneficiary; provided that, in each case, the transferee agrees in writing to be bound
by the terms and conditions of this Agreement and either the Stockholder or the transferee provides Molecular with a copy of such
agreement promptly upon consummation of any such Transfer and (ii) the Stockholder may take all actions reasonably necessary
to consummate the Contemplated Transactions, including, without limitation, effecting the Reverse Split. For purposes of this Agreement,
“immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.


 


1.3. No
Exercise of Appraisal Rights; Waivers. In connection with the Contemplated Transactions, the Stockholder hereby expressly
(a) waives, to the extent permitted under applicable Legal Requirements, the applicability of the provisions for dissenters’
or appraisal rights set forth in Section 262 of the DGCL (or any other similar applicable state Legal Requirement), with respect
to any Subject Shares, (b) agrees that the Stockholder will not, under any circumstances in connection with the Contemplated Transactions,
exercise any dissenters’ or appraisal rights in respect of any Subject Shares, and (c) agrees that the Stockholder will not
bring, commence, institute, maintain, prosecute, participate in or voluntarily aid any action, claim, suit or cause of action,
in law or in equity, in any court or before any Governmental Body, which (i) challenges the validity of or seeks to enjoin
the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the
Stockholder, or the approval of the Merger Agreement by the Threshold Board of Directors, breaches any fiduciary duty of the Threshold
Board of Directors or any member thereof; provided, that the Stockholder may defend against, contest or settle
any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder’s
capacity as a director, officer or securityholder of Threshold.


 




    2 


     


    

1.4. Documentation
and Information. The Stockholder shall permit and hereby authorizes Threshold and Molecular to publish and disclose in
all documents and schedules filed with the SEC, and any press release or other disclosure document that Threshold or Molecular
reasonably determines to be necessary in connection with the Merger and any transactions contemplated by the Merger Agreement,
the Stockholder’s identity and ownership of the Subject Shares and the nature of the Stockholder’s commitments and
obligations under this Agreement. Threshold is an intended third-party beneficiary of this Section 1.4.


 


1.5. Irrevocable
Proxy. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore
granted with respect to the Subject Shares. The Stockholder hereby irrevocably appoints Molecular as attorney-in-fact and proxy
for and on behalf of the Stockholder, for and in the name, place and stead of the Stockholder, to: (a) attend any and all
meetings of Threshold Stockholders, (b) vote, express consent or dissent or issue instructions to the record holder to vote
the Subject Shares in accordance with the provisions of Section 1.1 at any and all meetings of Threshold Stockholders
and (c) grant or withhold, or issue instructions to the record holder to grant or withhold, consistent with the provisions
of Section 1.1, all written consents with respect to the Subject Shares at any and all meetings of Threshold Stockholders.
Molecular agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement.
The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be
affected by the death, incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of the Merger
Agreement and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination
of this Agreement pursuant to Section 4.2. The Stockholder authorizes such attorney and proxy to substitute any other
Person to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary
of Threshold. The Stockholder hereby affirms that the proxy set forth in this Section 1.5 is given in connection with
and granted in consideration of and as an inducement to Molecular to enter into the Merger Agreement and that such proxy is given
to secure the obligations of the Stockholder under Section 1.1. The proxy set forth in this Section 1.5
is executed and intended to be irrevocable, subject, however, to its automatic termination upon the termination of this Agreement
pursuant to Section 4.2. With respect to any Subject Shares that are owned beneficially by the Stockholder but are
not held of record by the Stockholder, the Stockholder shall take all action necessary to cause the record holder of such Subject
Shares to grant the irrevocable proxy and take all other actions provided for in this Section 1.5 with respect to such
Subject Shares.


 


1.6. No Solicitation
of Transactions. The Stockholder shall not knowingly, directly or indirectly, through any officer, director, agent or otherwise,
(i) solicit, initiate, respond to or take any action knowingly to facilitate or encourage any inquiries or the communication, making,
submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected
to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) enter into or participate in any discussions or negotiations with
any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iii) furnish any information regarding such Party
to any Person in connection with, in response to, relating to or for the purpose of assisting with or facilitating an Acquisition
Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal (subject to Sections 5.2 and
5.3 of the Merger Agreement, as applicable); (v) execute or enter into any letter of intent or similar document or any Contract
contemplating or otherwise relating to any Acquisition Transaction other than a confidentiality agreement permitted under Section
4.5(c); or (vi) grant any waiver or release under any confidentiality, standstill or similar agreement. The Stockholder hereby
represents and warrants that the Stockholder has read Section 4.5 (No Solicitation) of the Merger Agreement
and agrees not to engage in any actions prohibited thereby.


 


1.7. No Ownership
Interest. Nothing contained in this Agreement will be deemed to vest in Molecular any direct or indirect ownership or incidents
of ownership of or with respect to the Subject


 




    3 


     


    

Shares. All rights, ownership and economic
benefits of and relating to the Subject Shares will remain and belong to the Stockholder, and Molecular will have no authority
to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of Threshold or exercise
any power or authority to direct Stockholder in the voting of any of the Subject Shares, except as otherwise expressly provided
herein with respect to the Subject Shares and except as otherwise expressly provided in the Merger Agreement.


 


ARTICLE II 


 


REPRESENTATIONS AND WARRANTIES OF THE
STOCKHOLDER 


 


The Stockholder represents and warrants
to Molecular that:


 


2.1. Organization;
Authorization; Binding Agreement. The Stockholder, if not a natural person, is duly incorporated or organized, as applicable,
validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has
full legal capacity and power, right and authority to execute and deliver this Agreement and to perform the Stockholder’s
obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed
and delivered by the Stockholder, and constitutes a legal, valid and binding obligation of the Stockholder enforceable against
the Stockholder in accordance with its terms, subject to (a) laws of general application relating to bankruptcy, insolvency
and the relief of debtors and (b) laws of general application relating to bankruptcy, insolvency, the relief of debtors, fraudulent
transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditor’s
rights (the “Enforceability Exceptions”).


 


2.2. Ownership
of Subject Shares; Total Shares. The Stockholder is the record or beneficial owner of the Subject Shares and has good and
marketable title to the Subject Shares free and clear of any Encumbrances (including any restriction on the right to vote or otherwise
transfer the Subject Shares), except (a) as provided hereunder, (b) pursuant to any applicable restrictions on transfer
under the Securities Act, and (c) subject to any risk of forfeiture with respect to any shares of Common Stock granted to
the Stockholder under an employee benefit plan of Threshold. The Subject Shares listed on Schedule A opposite the Stockholder’s
name constitute all of the shares of Common Stock owned by the Stockholder as of the date hereof. No Person has any contractual
or other right or obligation to purchase or otherwise acquire any of the Subject Shares. For purposes of this Agreement “Beneficial
Ownership” shall be interpreted as defined in Rule 13d-3 under the Exchange Act; provided that for purposes of determining
Beneficial Ownership, a Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person
pursuant to any Contract or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise (irrespective
of whether the right to acquire such securities is exercisable immediately or only after the passage of time, including the passage
of time in excess of 60 days, the satisfaction of any conditions, the occurrence of any event or any combination of the foregoing).


 


2.3. Voting
Power. The Stockholder has full voting power, with respect to the Subject Shares, and full power of disposition, full power
to issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this
Agreement, in each case, with respect to all of the Subject Shares. None of the Subject Shares are subject to any proxy, voting
trust or other agreement or arrangement with respect to the voting of the Subject Shares except as provided hereunder.


 


2.4. Reliance.
The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder’s
own choosing. The Stockholder understands and


 




    4 


     


    

acknowledges that Molecular is entering
into the Merger Agreement in reliance upon the Stockholder’s execution, delivery and performance of this Agreement.


 


2.5. Absence
of Litigation. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding
pending against, or, to the knowledge of the Stockholder, threatened in writing against, the Stockholder or any of the Stockholder’s
properties or assets (including the Subject Shares) that could reasonably be expected to prevent, delay or impair the ability of
the Stockholder to perform the Stockholder’s obligations hereunder or to consummate the transactions contemplated hereby.


 


2.6. Non-Contravention.
The execution and delivery of this Agreement by the Stockholder and the performance of the transactions contemplated by this Agreement
by the Stockholder does not and will not violate, conflict with, or result in a breach of (a) any applicable Legal Requirement
or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental Body to which the Stockholder
is subject; or (b) any Contract to which the Stockholder is a party or is bound or to which the Stockholder’s Subject Shares
are subject.


 


ARTICLE III 


 


REPRESENTATIONS AND WARRANTIES OF MOLECULAR



 


Molecular represents and warrants to the
Stockholder that:


 


3.1. Organization;
Authorization. Molecular is a corporation duly incorporated, validly existing and in good standing under the laws of the
State of Delaware. The consummation of the transactions contemplated hereby is within Molecular’s corporate powers and have
been duly authorized by all necessary corporate actions on the part of Molecular. Molecular has full power and authority to execute,
deliver and perform this Agreement.


 


3.2. Binding
Agreement. This Agreement has been duly authorized, executed and delivered by Molecular and constitutes a valid and binding
obligation of Molecular enforceable against Molecular in accordance with its terms, subject to the Enforceability Exceptions.


 


ARTICLE IV 


 


MISCELLANEOUS 


 


4.1. Notices.
All notices, requests and other communications to either party hereunder shall be in writing (including facsimile transmission
or electronic mail) and shall be given, (a) if to Molecular, in accordance with the provisions of the Merger Agreement and
(b) if to the Stockholder, to the Stockholder’s address, electronic mail address or facsimile number set forth on a
signature page hereto, or to such other address, electronic mail address or facsimile number as the Stockholder may hereafter specify
in writing to Molecular.


 


4.2. Termination.
This Agreement shall terminate automatically, without any notice or other action by any Person, upon the earlier of (a) the
termination of the Merger Agreement in accordance with its terms and (b) the Effective Time. Upon termination of this Agreement,
neither party shall have any further obligations or liabilities under this Agreement; provided, however, that (i) nothing
set forth in this Section 4.2 shall relieve either party from liability for any breach of this Agreement prior to termination
hereof, and (ii) the provisions of this Article IV shall survive any termination of this Agreement.


 




    5 


     


    

4.3. Amendments
and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is
signed, in the case of an amendment, by each party to this Agreement, in the case of a waiver, by the party against whom the waiver
is to be effective. No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as
a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege.


 


4.4. Binding
Effect; Benefit; Assignment. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the
parties hereto and their respective successors and assigns. Except as set forth in Section 1.4, no provision of this
Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any person other than
the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of
its rights or obligations under this Agreement without the consent of the other party hereto, except that Molecular may transfer
or assign its rights and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates
at any time; provided, that such transfer or assignment shall not relieve Molecular of any of its obligations hereunder.


 


4.5. Governing
Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware,
regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or suit between
any of the parties arising out of or relating to this Agreement: (a) each of the parties irrevocably and unconditionally consents
and submits to the exclusive jurisdiction and venue of the Delaware Court of Chancery, or if such court does not have proper jurisdiction,
then the federal courts located in the State of Delaware, and appellate courts therefrom (collectively, the “Delaware
Courts”); and (b) each of the parties irrevocably waives the right to trial by jury.


 


4.6. Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute
one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile
or electronic transmission in .PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.


 


4.7. Entire
Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both
written and oral, among or between any of the parties with respect to the subject matter hereof and thereof.


 


4.8. Severability.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect
the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the
offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction
declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making
such determination will have the power to limit such term or provision, to delete specific words or phrases or to replace such
term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of
the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event
such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or
unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic,
business and other purposes of such invalid or unenforceable term or provision.


 


4.9. Specific
Performance. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive
of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not
preclude the exercise of any other remedy.


 




    6 


     


    

The parties hereto agree that irreparable
damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific
terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to
prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any Delaware Court, this being
in addition to any other remedy to which they are entitled at law or in equity, and each of the parties hereto waives any bond,
surety or other security that might be required of any other party with respect thereto.


 


4.10.
Construction. 


 


(a)     
For purposes of this Agreement, whenever the context requires: the singular number
shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender
shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.


 


(b)     
The parties hereto agree that any rule of construction to the effect that ambiguities
are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.


 


(c)      
As used in this Agreement, the words “include” and “including,”
and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without
limitation.” 


 


(d)     
Except as otherwise indicated, all references in this Agreement to “Sections,”
“Articles,” and “Schedules” are intended to refer to Sections or Articles of this Agreement and Schedules
to this Agreement, respectively.


 


(e)      
The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed
to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.


 


4.11. Further
Assurances. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents
and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause
to be done, all things necessary under applicable Legal Requirements to perform their respective obligations as expressly set forth
under this Agreement.


 


4.12. Capacity
as Stockholder. The Stockholder signs this Agreement solely in the Stockholder’s capacity as a Stockholder of Threshold,
and not in the Stockholder’s capacity as a director, officer or employee of Threshold or any of its Subsidiaries or in the
Stockholder’s capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to
the contrary, nothing herein shall in any way restrict a director or officer of Threshold in the exercise of his or her fiduciary
duties as a director or officer of Threshold or in his or her capacity as a trustee or fiduciary of any employee benefit plan or
trust or prevent or be construed to create any obligation on the part of any director or officer of Threshold or any trustee or
fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee
or fiduciary.


 


4.13. No Agreement
Until Executed. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement
shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless
and until (a) the board of directors of Threshold has approved, for purposes of any applicable anti-takeover laws and regulations,


 




    7 


     


    

and any applicable provision of Threshold’s
organizational documents, the Merger, (b) the Merger Agreement is executed by all parties thereto, and (c) this Agreement
is executed by all parties hereto.


 


 


 


(SIGNATURE PAGE FOLLOWS)


 




    8 


     


    

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed as of the date first written above.


 


 


 


	 	 	 	 
	 	MOLECULAR TEMPLATES, INC.
	 	 	 
	 	By:	 	
 


	 	 	 	Name: Eric E. Poma, Ph.D.
	 	 	 	Title: Chief Executive Officer


 


 


 





[Signature Page to Support Agreement]


 









     


     


    

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed as of the date first written above.


 


 





	 	STOCKHOLDER	 
	 	 	 
	 	 	 
	 	(Print Name of Stockholder)	 
	 	 	 
	 	 	 
	 	(Signature)	 
	 	 	 
	 	 	 
	 	(Name and Title of Signatory, if Signing	 
	 	 on Behalf of an Entity)	 
	 	 	 







 





 


 





[Signature Page to Support Agreement]


 









     


     


    

Schedule A


 


 


 


	 	 	 
	
        Name of Stockholder
	 	No. Shares